Sandra Ryeom

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch
    Sylvie Giuriato
    Departments of Medicine and Pathology, Division of Oncology, Stanford University School of Medicine, CCSR Building, Room 1120, 269 Campus Drive, Stanford, CA 94305 5151, USA
    Proc Natl Acad Sci U S A 103:16266-71. 2006
  2. ncbi Role of endogenous angiogenesis inhibitors in Down syndrome
    Sandra Ryeom
    Vascular Biology Program, Department of Surgery, Children s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Craniofac Surg 20:595-6. 2009
  3. ncbi Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth
    Sandra Ryeom
    Vascular Biology Program, Department of Surgery, Children s Hospital, Boston, MA 02115, USA
    Cancer Cell 13:420-31. 2008
  4. ncbi Differential effects of VEGFR-1 and VEGFR-2 inhibition on tumor metastases based on host organ environment
    Yoon Jin Lee
    Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Cancer Res 70:8357-67. 2010
  5. ncbi Variable inhibition of thrombospondin 1 against liver and lung metastases through differential activation of metalloproteinase ADAMTS1
    Yoon Jin Lee
    Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Cancer Res 70:948-56. 2010
  6. ncbi Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1
    Kwan Hyuck Baek
    Vascular Biology Program, Department of Surgery, Children s Hospital Boston, Massachusetts 02115, USA
    Nature 459:1126-30. 2009
  7. ncbi Regional control of tumor growth
    Alexander Zaslavsky
    Vascular Biology Program and Department of Surgery, Children s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Mol Cancer Res 8:1198-206. 2010
  8. ncbi Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors
    Namali T Fernando
    Division of Surgical Oncology, Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Clin Cancer Res 14:1529-39. 2008
  9. ncbi Circulating endothelial progenitor cells are up-regulated in a mouse model of endometriosis
    Christian M Becker
    Vascular Biology Program, Children s Hospital Boston, Harvard Medical School, Boston, Massachusetts, USA
    Am J Pathol 178:1782-91. 2011
  10. ncbi Efficacy of sunitinib and radiotherapy in genetically engineered mouse model of soft-tissue sarcoma
    Sam S Yoon
    Department of Surgery, Division of Surgical Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Int J Radiat Oncol Biol Phys 74:1207-16. 2009

Collaborators

Detail Information

Publications16

  1. ncbi Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch
    Sylvie Giuriato
    Departments of Medicine and Pathology, Division of Oncology, Stanford University School of Medicine, CCSR Building, Room 1120, 269 Campus Drive, Stanford, CA 94305 5151, USA
    Proc Natl Acad Sci U S A 103:16266-71. 2006
    ..Therefore, the combined inactivation of oncogenes and angiogenesis may be a more clinically effective treatment of cancer. We conclude that angiogenesis is an essential component of oncogene addiction...
  2. ncbi Role of endogenous angiogenesis inhibitors in Down syndrome
    Sandra Ryeom
    Vascular Biology Program, Department of Surgery, Children s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Craniofac Surg 20:595-6. 2009
    ..The molecular regulation of angiogenesis is not yet fully understood; however, the Down syndrome population may give us insights toward novel therapies for controlling angiogenesis in disease...
  3. ncbi Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth
    Sandra Ryeom
    Vascular Biology Program, Department of Surgery, Children s Hospital, Boston, MA 02115, USA
    Cancer Cell 13:420-31. 2008
    ..Treatment with the specific pharmacological calcineurin inhibitor cyclosporin A rescues this endothelial defect in DSCR1(-/-) mice, restoring tumor growth...
  4. ncbi Differential effects of VEGFR-1 and VEGFR-2 inhibition on tumor metastases based on host organ environment
    Yoon Jin Lee
    Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Cancer Res 70:8357-67. 2010
    ..Thus, therapies inhibiting specific VEGFRs should consider the targeted sites of metastatic disease...
  5. ncbi Variable inhibition of thrombospondin 1 against liver and lung metastases through differential activation of metalloproteinase ADAMTS1
    Yoon Jin Lee
    Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Cancer Res 70:948-56. 2010
    ..Collectively, our results indicate that the antiangiogenic activity of TSP1 is differentially regulated by ADAMTS1 in the liver and lung, emphasizing the concept that regulation of angiogenesis is varied in different tissue environments...
  6. ncbi Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1
    Kwan Hyuck Baek
    Vascular Biology Program, Department of Surgery, Children s Hospital Boston, Massachusetts 02115, USA
    Nature 459:1126-30. 2009
    ....
  7. ncbi Regional control of tumor growth
    Alexander Zaslavsky
    Vascular Biology Program and Department of Surgery, Children s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Mol Cancer Res 8:1198-206. 2010
    ..Finally, our studies suggest that upregulation of TSP-1 in tumor cells is one method to suppress the growth of tumors in the upper abdomen...
  8. ncbi Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors
    Namali T Fernando
    Division of Surgical Oncology, Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Clin Cancer Res 14:1529-39. 2008
    ..Thrombospondin-1 (Tsp1), endostatin, and tumstatin are extracellular matrix-associated proteins that inhibit angiogenesis. We examined the mechanisms by which tumor cells may bypass the antiangiogenic effects of these endogenous regulators...
  9. ncbi Circulating endothelial progenitor cells are up-regulated in a mouse model of endometriosis
    Christian M Becker
    Vascular Biology Program, Children s Hospital Boston, Harvard Medical School, Boston, Massachusetts, USA
    Am J Pathol 178:1782-91. 2011
    ....
  10. ncbi Efficacy of sunitinib and radiotherapy in genetically engineered mouse model of soft-tissue sarcoma
    Sam S Yoon
    Department of Surgery, Division of Surgical Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Int J Radiat Oncol Biol Phys 74:1207-16. 2009
    ..The present study examined SU and radiotherapy (RT) in a genetically engineered mouse model of soft tissue sarcoma (STS)...
  11. ncbi TORC1 is essential for NF1-associated malignancies
    Cory M Johannessen
    Genetics Division, Department of Medicine, Brigham and Women s Hospital, Ludwig Center at Dana Farber Harvard Cancer Center, Harvard Medical School, Boston, Massachusetts 02115, USA
    Curr Biol 18:56-62. 2008
    ....
  12. ncbi An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB
    Junxia Min
    Genetics Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Nat Med 16:286-94. 2010
    ..These studies define the mechanism by which two major pathways can be simultaneously activated in metastatic prostate cancer and establish EZH2 as a driver of metastasis...
  13. ncbi The threshold pattern of calcineurin-dependent gene expression is altered by loss of the endogenous inhibitor calcipressin
    Sandra Ryeom
    Department of Cell Biology, Harvard Medical School, 240 Longwood Avenue, Boston, Massachusetts 02115, USA
    Nat Immunol 4:874-81. 2003
    ..Thus, calcipressins modulate the pattern of calcineurin-dependent transcription, and may influence calcineurin activity beyond calcium to integrate a broad array of signals into the cellular response...
  14. ncbi Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium
    Paul Beaudry
    Department of Vascular Biology, Boston Children s Hospital, Boston, Massachusetts, USA
    Mol Cancer Ther 7:418-24. 2008
    ..In conclusion, dual targeting of tumor cells, potentially through RET inhibition, and tumor vasculature with ZD6474 leads to potent antitumor effects. This approach merits further investigation for patients with neuroblastoma...
  15. ncbi Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released
    Joseph E Italiano
    Translational Medicine Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    Blood 111:1227-33. 2008
    ....
  16. ncbi Endothelial progenitor cells contribute to accelerated liver regeneration
    Paul Beaudry
    Vascular Biology Program, Department of Surgery, Children s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Pediatr Surg 42:1190-8. 2007
    ..These results suggest that CEP cells play a role in regulating liver regeneration and that VEGF treatment can mobilize CEP cells to accelerate this process...